EHA 2022 | Updates from the COBALT-LYM study: CTX130 in patients with R/R T-cell malignancies
Swaminathan Iyer
• 10 Jun 2022
Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some findings from the COBALT-LYM study (NCT04502446), evaluating the safety and efficacy of CTX130, a novel, allogeneic CAR-T cell therapy, in patients with relapsed/refractory (R/R) T-cell lymphomas. Dr Iyer first highlights the patient population enrolled in this study, and then goes on to discuss some of the key results, including the overall response rate (ORR) observed and the promise of this agent for the treatment of T-cell malignancies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE
